• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Could Antibodies or Hormones Slow Brain Damage from Alzheimer’s?
Scientists have discovered that certain antibodies may help slow the progression of Alzheimer’s disease. Dr. Patricia Salinas of University College London, UK, and her team focused on a protein called Dkk1, present in raised levels in the brains of people with Alzheimer’s disease. Using brain samples from mice, the team looked at the progressive disintegration of synapses in the hippocampus when exposed to a protein called amyloid-beta, thought to be central to the development of Alzheimer’s disease. “Synaptic loss mediated by amyloid-beta in early stages of the disease might contribute to cognitive...
Source: Psych Central - June 1, 2013 Category: Psychiatry Authors: Jane Collingwood Tags: Aging Alzheimer's Disorders General Seniors Abnormal Deposits Alzheimer S Disease Antibodies Brain Area Brain Damage Cognitive Decline Cognitive Impairments Disintegration Dr Patricia Dr Simon Hippocampus Journal Of Neurosc Source Type: news

Green tea compound may improve cancer drugs
Conclusion This study developed a new way of packaging and carrying protein drugs by combining them with a green tea extract called Epigallocatechin-3-O-gallate (EGCG), which itself may have anti-cancer properties. They formed a complex between derivatives of EGCG and the protein cancer drug Herceptin. Tests in the laboratory and in mice indicated it might have better anti-cancer properties than non-complexed free Herceptin. This is encouraging research and may lead to improvements in delivery mechanisms for protein drugs further down the line. But this research remains at a very early stage of development. The results f...
Source: NHS News Feed - October 6, 2014 Category: Consumer Health News Tags: Cancer Medication Source Type: news

Abstract PD4-07: Are aromatase inhibitors associated with higher myocardial infarction risk in breast cancer patients? A Medicare population study
Conclusions: The occurrence of MI is very low in this cohort (4.4%), reassuring the clinicians that the older adults with comorbidities may not be at a higher risk of MI with adjuvant endocrine therapy. However, the confidence interval for the hazard ratio of AIs vs Tamoxifen is very wide, indicating that a larger sample may be needed for the power of the study to be conclusive.Citation Format: Kamaraju S, Smith E, Shi Y, Laud P, Neuner J. Are aromatase inhibitors associated with higher myocardial infarction risk in breast cancer patients? A Medicare population study [abstract]. In: Proceedings of the Thirty-Ninth Annual C...
Source: Cancer Research - February 13, 2017 Category: Cancer & Oncology Authors: S Kamaraju, E Smith, Y Shi, P Laud, J Neuner Tags: Poster Discussion Abstracts Source Type: research

Targeted Cancer Therapies.
Abstract Targeted cancer therapies involve chemotherapeutic agents that attack, directly or indirectly, a specific genetic biomarker found in a given cancer. Targeted oncology includes monoclonal antibodies, small molecule inhibitors, antibody-drug conjugates, and immunotherapy. For example, the monoclonal antibodies trastuzumab and pertuzumab target human epidermal growth factor receptor 2 (HER2) and are used when treating HER2-positive breast cancer. Although targeted oncology has improved survival by years for some incurable cancers such as metastatic breast and lung cancer, as few as 8% of patients with advanc...
Source: American Family Physician - January 30, 2021 Category: Primary Care Authors: Smith CEP, Prasad V Tags: Am Fam Physician Source Type: research

Baseline cardiovascular comorbidities, and the influence on cancer treatment decision-making in women with breast cancer
CONCLUSION: While recent guidelines recommend routine assessment of cardiovascular comorbidities in cancer patients prior to initiation of anticancer therapies, this study highlights the prevailing gap in knowledge on how such data may be used to optimise cancer treatment decision-making.PMID:34824616 | PMC:PMC8580595 | DOI:10.3332/ecancer.2021.1293
Source: Ecancermedicalscience - November 26, 2021 Category: Cancer & Oncology Authors: Shridevi Subramaniam Yek-Ching Kong Hafizah Zaharah Cuno S P M Uiterwaal Andrea Richard Nur Aishah Taib Azura Deniel Kok-Han Chee Ros Suzanna Bustamam Mee-Hoong See Alan Fong Cheng-Har Yip Nirmala Bhoo-Pathy Source Type: research

Pages: 1  2  3